Scorpius Holdings (SCPX) announced a strategic partnership with a U.S.-based biotech company. Under this agreement, the biotech company will work with Scorpius’ program management team, with plans to transfer a research cell bank, RCB, to Scorpius’ state-of-the-art facilities in San Antonio, TX for future biomanufacturing activities. “This partnership underscores Scorpius’ ability to support biotech companies at every stage of their journey, from innovative research to clinical trials,” said Jeff Wolf, CEO of Scorpius. “We are seeing a growing number of biotech companies seeking U.S.-based biomanufacturing partners, and Scorpius is equipped to provide early-stage development, preclinical manufacturing, and cGMP clinical manufacturing for both mammalian and microbial programs.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPX:
- Scorpius Holdings selected to join Medical CBRN Defense Consortium
- Scorpius signs contract to provide bioanalytical services to biotech company
- Scorpius Holdings initiated with a Buy at ThinkEquity
- Scorpius Holdings commends passage of the BIOSECURE Act
- Scorpius Holdings selected for RRPV to accelerate countermeasure development